Quantitative prediction of renal transporter-mediated clinical drug-drug interactions.

Kidney plays a critical role in the elimination of xenobiotics. Drug-drug interactions (DDIs) via inhibition of renal organic anion (OAT) and organic cation (OCT) transporters have been observed in the clinic. This study examined the quantitative predictability of renal transporter-mediated clinical DDIs based on basic and mechanistic models. In vitro transport and clinical pharmacokinetics parameters were used to quantitatively predict DDIs of victim drugs when coadministrated with OAT or OCT inhibitors, probenecid and cimetidine, respectively. The predicted changes in renal clearance (CLr) and area under the plasma concentration-time curve (AUC) were comparable to that observed in clinical studies. With probenecid, basic modeling predicted 61% cases within 25% and 94% cases within 50% of the observed CLr changes in clinic. With cimetidine, basic modeling predicted 61% cases within 25% and 92% cases within 50% of the observed CLr changes in clinic. Additionally, the mechanistic model predicted 54% cases within 25% and 92% cases within 50% of the observed AUC changes with probenecid. Notably, the magnitude of AUC changes attributable to the renal DDIs is generally less than 2-fold, unlike the DDIs associated with inhibition of CYPs and/or hepatic uptake transporters. The models were further used to evaluate the renal DDIs of Pfizer clinical candidates/drugs, and the overall predictability demonstrates their utility in the drug discovery and development settings.

[1]  Yuichi Sugiyama,et al.  Transporters as a determinant of drug clearance and tissue distribution. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[2]  Osamu Ogawa,et al.  Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. , 2007, Biochemical pharmacology.

[3]  R. Obach,et al.  Physicochemical determinants of human renal clearance. , 2009, Journal of medicinal chemistry.

[4]  D. Jung,et al.  Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[5]  H. Endou,et al.  Characterization of organic anion transport inhibitors using cells stably expressing human organic anion transporters. , 2001, European journal of pharmacology.

[6]  S. Passe,et al.  The Effect of Probenecid on the Pharmacokinetics of Zalcitabine in HIV-Positive Patients , 1996, Pharmaceutical Research.

[7]  A. Somogyi,et al.  Pharmacokinetic Interactions of Cimetidine 1987 , 1987, Clinical pharmacokinetics.

[8]  M. Nakano,et al.  The Inhibitory Effect of Probenecid on Renal Excretion of Famotidine in Young, Healthy Volunteers , 1990, Journal of clinical pharmacology.

[9]  E. Fauman,et al.  Pharmacology and mechanism of action of pregabalin: The calcium channel α2–δ (alpha2–delta) subunit as a target for antiepileptic drug discovery , 2007, Epilepsy Research.

[10]  F. Sörgel,et al.  Effect of probenecid on the distribution and elimination of ciprofloxacin in humans , 1995, Clinical pharmacology and therapeutics.

[11]  M. Eve,et al.  Effect of cimetidine and ranitidine on pharmacokinetics and pharmacodynamics of a single dose of dofetilide. , 2000, British journal of clinical pharmacology.

[12]  Satohiro Masuda,et al.  Involvement of Human Multidrug and Toxin Extrusion 1 in the Drug Interaction between Cimetidine and Metformin in Renal Epithelial Cells , 2009, Journal of Pharmacology and Experimental Therapeutics.

[13]  K. Giacomini,et al.  The effect of probenecid on the renal elimination of cimetidine , 1989, Clinical pharmacology and therapeutics.

[14]  G. Burckart,et al.  Probenecid, but Not Cystic Fibrosis, Alters the Total and Renal Clearance of Fexofenadine , 2008, Journal of clinical pharmacology.

[15]  R. Ramsay,et al.  Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy , 1998, Epilepsy Research.

[16]  D. A. Page,et al.  Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans , 1982, Antimicrobial Agents and Chemotherapy.

[17]  B. Feng,et al.  Effect of Human Renal Cationic Transporter Inhibition on the Pharmacokinetics of Varenicline, a New Therapy for Smoking Cessation: An In Vitro–In Vivo Study , 2008, Clinical pharmacology and therapeutics.

[18]  H. Koepsell,et al.  Polyspecific Organic Cation Transporters: Structure, Function, Physiological Roles, and Biopharmaceutical Implications , 2007, Pharmaceutical Research.

[19]  R. Sonders,et al.  Effect of probenecid on the pharmacokinetics of cefmenoxime , 1983, Antimicrobial Agents and Chemotherapy.

[20]  B. Feng,et al.  Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state , 2010, Expert opinion on drug metabolism & toxicology.

[21]  A. Sedman,et al.  Pharmacokinetics of Pregabalin in Subjects with Various Degrees of Renal Function , 2003, Journal of clinical pharmacology.

[22]  C. Hovens,et al.  Renal tubular secretion of amiloride and its inhibition by cimetidine in humans and in an animal model. , 1989, Drug metabolism and disposition: the biological fate of chemicals.

[23]  D. Jung,et al.  Interaction of Steady‐State Procainamide with H2‐Receptor Antagonists Cimetidine and Ranitidine , 1987, Therapeutic drug monitoring.

[24]  Eiji Takeda,et al.  Expression Cloning and Characterization of a Transporter for Large Neutral Amino Acids Activated by the Heavy Chain of 4F2 Antigen (CD98)* , 1998, The Journal of Biological Chemistry.

[25]  F. Russel,et al.  Mechanisms and clinical implications of renal drug excretion* , 2001, Drug metabolism reviews.

[26]  H. Kusuhara,et al.  Involvement of MRP4 (ABCC4) in the Luminal Efflux of Ceftizoxime and Cefazolin in the Kidney , 2007, Molecular Pharmacology.

[27]  H. Black,et al.  Cinoxacin: Pharmacokinetics and the Effect of Probenecid , 1978, Journal of clinical pharmacology.

[28]  N. Yasui-Furukori,et al.  Different Effects of Three Transporting Inhibitors, Verapamil, Cimetidine, and Probenecid, on Fexofenadine Pharmacokinetics , 2005, Clinical pharmacology and therapeutics.

[29]  A. Dolphin,et al.  Identification of the (cid:1) 2 - (cid:2) -1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin , 2006 .

[30]  W. Elmquist,et al.  Probenecid Inhibits the Metabolic and Renal Clearances of Zidovudine (AZT) in Human Volunteers , 1990, Pharmaceutical Research.

[31]  A. Lant,et al.  Pharmacokinetic and pharmacodynamic actions of enalapril in humans: effect of probenecid pretreatment. , 1990, The Journal of pharmacology and experimental therapeutics.

[32]  K. Giacomini,et al.  Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters. , 2001, Journal of pharmaceutical sciences.

[33]  M. Polis,et al.  Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients , 1995, Antimicrobial agents and chemotherapy.

[34]  S. Ekins,et al.  Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. , 2003, Molecular pharmacology.

[35]  B. Corrigan,et al.  Clinical Pharmacokinetics of Pregabalin in Healthy Volunteers , 2010, Journal of clinical pharmacology.

[36]  Li Di,et al.  pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery. , 2012, Molecular pharmaceutics.

[37]  M. R. Feng,et al.  Mediation of Highly Concentrative Uptake of Pregabalin by L-Type Amino Acid Transport in Chinese Hamster Ovary and Caco-2 Cells , 2005, Journal of Pharmacology and Experimental Therapeutics.

[38]  Brian Tomlinson,et al.  OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine , 2008, Pharmacogenetics and genomics.

[39]  W. F. White,et al.  Prolongation and enhancement of serum methotrexate concentrations by probenecid. , 1978, British medical journal.

[40]  M. Okuda,et al.  Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). , 2004, European journal of pharmacology.

[41]  D. Brater,et al.  Pharmacodynamic analysis of the furosemide-probenecid interaction in man. , 1979, Kidney international.

[42]  P. Rolan,et al.  Multiple Interactions of Cimetidine and Probenecid with Valaciclovir and Its Metabolite Acyclovir , 2002, Antimicrobial Agents and Chemotherapy.

[43]  Malcolm Rowland,et al.  Kinetics of drug-drug interactions , 1973, Journal of Pharmacokinetics and Biopharmaceutics.

[44]  P. Ward,et al.  The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[45]  T. Burke,et al.  Interaction of Alkyl/Arylphosphonates, phosphonocarboxylates and diphosphonates with different anion transport systems in the proximal renal tubule. , 1997, The Journal of pharmacology and experimental therapeutics.

[46]  K. Speeg,et al.  Cimetidine inhibits renal procainamide clearance , 1984, Clinical pharmacology and therapeutics.

[47]  A. Somogyi,et al.  Cimetidine-procainamide pharmacokinetic interaction in man: Evidence of competition for tubular secretion of basic drugs , 2004, European Journal of Clinical Pharmacology.

[48]  A. Somogyi,et al.  Selectivity of the cimetidine-induced alterations in the renal handling of organic substrates in humans. Studies with anionic, cationic and zwitterionic drugs. , 1986, The Journal of pharmacology and experimental therapeutics.

[49]  E. S. Waller,et al.  The Effect of Probenecid on Nafcillin Disposition , 1982, Journal of clinical pharmacology.

[50]  H. Black,et al.  Effect of Probenecid on the Blood Levels and Urinary Excretion of Cefamandole , 1977, Antimicrobial Agents and Chemotherapy.

[51]  B. Beermann,et al.  Coupling between renal tubular secretion and effect of bumetanide , 1983, Clinical pharmacology and therapeutics.

[52]  B. Beermann,et al.  Non-linear elimination and protein binding of probenecid , 2004, European Journal of Clinical Pharmacology.